Therachon

Acquired

Basel, Switzerland · Founded 2016 · $100.0M raised

Headquarters
Basel
Employees
11–50
Founded
2016
Business Model
B2B
Total Funding
$100.0M
Last Round
$60.0M Series BAug 2018
Rounds
3
Acquired by
PfizerJun 2019 · $340.0M

About

Therachon AG was a clinical-stage global biotechnology company headquartered in Basel, Switzerland, focused on developing innovative treatments for rare genetic diseases with no available therapies. Its lead program, TA-46 (recifercept), was a novel protein therapy targeting achondroplasia — the most common form of short-limbed dwarfism — designed to restore normal bone growth. The company received Orphan Drug Designations from both the FDA and EMA and advanced TA-46 into Phase 1 clinical trials before being acquired by Pfizer in May 2019 for up to $810 million.

Summary

Therachon is a Biotech company based in Basel, Switzerland, founded in 2016. It has raised $100.0M in total across 3 rounds, most recently a $60.0M Series B round in Aug 2018. Investors include Pfizer Ventures, Novo Holdings A/S and Bpifrance.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

AcquisitionJun 2019

Sign up to see all 4 rounds

Series A through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Therachon on Indexed.vc
<a href="https://indexed.vc/companies/therachon"><img src="https://indexed.vc/api/badge/company/therachon" alt="Therachon on Indexed.vc" width="260" height="76" /></a>